Mark Reynolds - ConvaTec Group Director Relations
| CNVVF Stock | USD 2.95 0.10 3.51% |
Insider
Mark Reynolds is Director Relations of ConvaTec Group Plc
| Phone | 44 11 8952 8100 |
| Web | https://www.convatecgroup.com |
Mark Reynolds Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Reynolds against ConvaTec Group pink sheet is an integral part of due diligence when investing in ConvaTec Group. Mark Reynolds insider activity provides valuable insight into whether ConvaTec Group is net buyers or sellers over its current business cycle. Note, ConvaTec Group insiders must abide by specific rules, including filing SEC forms every time they buy or sell ConvaTec Group'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Reynolds over six months ago Purchase by Mark Reynolds of 2000 shares of GeoVax Labs | ||
Mark Reynolds over a year ago Purchase by Mark Reynolds of 10000 shares of GeoVax Labs | ||
Mark Reynolds over a year ago Acquisition by Mark Reynolds of 100000 shares of GeoVax Labs subject to Rule 16b-3 | ||
Mark Reynolds over a year ago Purchase by Mark Reynolds of 8000 shares of GeoVax Labs |
ConvaTec Group Management Efficiency
The company has return on total asset (ROA) of 0.0354 % which means that it generated a profit of $0.0354 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0486 %, meaning that it generated $0.0486 on every $100 dollars invested by stockholders. ConvaTec Group's management efficiency ratios could be used to measure how well ConvaTec Group manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | INSIDER Age | ||
| Rachel Vaknin | Microbot Medical | 45 | |
| Esq CPA | GlucoTrack | 59 | |
| Pr DSc | Microbot Medical | 72 | |
| Steven MD | Sharps Technology | 62 | |
| Robert Hayes | Sharps Technology | 57 | |
| Barry Berler | Sharps Technology | 70 | |
| Erez BenZvi | GlucoTrack | 46 | |
| Alan Blackman | Sharps Technology | 75 | |
| David BA | GlucoTrack | 59 | |
| MScEE MBA | GlucoTrack | 70 | |
| Eyal MD | Microbot Medical | 59 | |
| Andrew CPA | Sharps Technology | 68 | |
Management Performance
| Return On Equity | 0.0486 | |||
| Return On Asset | 0.0354 |
ConvaTec Group Plc Leadership Team
Elected by the shareholders, the ConvaTec Group's board of directors comprises two types of representatives: ConvaTec Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ConvaTec. The board's role is to monitor ConvaTec Group's management team and ensure that shareholders' interests are well served. ConvaTec Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ConvaTec Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Schulkes, CFO - Designate | ||
| Karim Bitar, CEO Director | ||
| Supratim Bose, Executive Vice President and President APAC | ||
| Natalia Kozmina, Ex Officer | ||
| Mark Reynolds, Director Relations | ||
| Jonathan Mason, Group Director | ||
| Donal Balfe, Executive Vice President - Global Operations | ||
| Divakar Ramakrishnan, Ex Officer | ||
| Kate Postans, VP Communications | ||
| MSc Biotechnology, Pres Care | ||
| Christian Hoengaard, VP USA |
ConvaTec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is ConvaTec Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0486 | |||
| Return On Asset | 0.0354 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 0.10 % | |||
| Current Valuation | 6.84 B | |||
| Shares Outstanding | 2.04 B | |||
| Shares Owned By Insiders | 19.77 % | |||
| Shares Owned By Institutions | 60.64 % | |||
| Price To Earning | 47.32 X | |||
| Price To Book | 3.51 X |
Currently Active Assets on Macroaxis
Other Information on Investing in ConvaTec Pink Sheet
ConvaTec Group financial ratios help investors to determine whether ConvaTec Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ConvaTec with respect to the benefits of owning ConvaTec Group security.